Editorial StaffWe saw large market declines as 2022 got started – but the real story was the increase in volatility. Especially at the beginning of February, when the market losses leveled off, daily trading was characterized by strong swings up and down. It’s a situation that puts a burden on investors, to recognize the right time to buy in for optimal profits.
The key is not to try and ‘time’ it on daily trading, but to look at longer trends and future predictors. One place to find indicators toward a stock’s near- to mid-term performance is in the buying history of its insiders. These are the corporate officers who steer their companies and know the day-to-day workings of the firms. This knowledge puts them on an inside track when it comes to trading their own company’s stocks – but market regulators require them to publish these trades as a way to level the field. Retail investors can watch those published insider moves; they bring a sometimes-insightful data point to the trading table.
Investors can look to these moves, using TipRanks’ Insiders Hot Stocks tool. We’ve used that tool to do just that, find a couple of stocks whose price has dropped over the past year – and that drop has coincided with some ‘informative buy’ insider trades. Let’s take a closer look.
Rocket Pharmaceuticals (RCKT)
The first insider pick here, Rocket Pharmaceuticals, is a clinical-stage biotech company focused on gene therapy. These are novel treatment options for diseases with ‘high unmet medical needs,’ usually genetic diseases that lead to potentially terminal cancers and pediatric conditions. These therapies offer the potential for cures, at the genetic level within affected cells. Rocket has several clinical-stage programs in progress, targeting a range of conditions, including Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency (LAD-I), and Pyruvate Kinase Deficiency (PKD). The company’s programs use associated viral vector (AAV) and lentiviral vector (LVV) modes as delivery pathways.
Rocket has multiple catalysts coming up this year, on all four of these research tracks. The most advanced program, for LAD-I, recently completed a 9-patient Phase 1/2 clinical trial. The drug candidate showed a favorable safety profile in the trial, along with some initial clinical benefit to patients. LAD-I is a dangerous pediatric disease, in which infant children are unable to fend off infection; it is currently treatable through bone marrow transplants. Rocket’s RP-L201 drug candidate aims to correct the affected gene in white blood cells. In Q2 of this year, Rocket will be reporting top line data from the pivotal Phase 2 part of the trial.
The company will also be reporting top line pivotal Phase 2 data on its clinical trial of RP-L102 for Fanconi Anemia. This data will be reported in 3Q22. Fanconi Anemia is another pediatric condition, in which a defective FANCA gene may lead to bone marrow failure or blood cancers. The RP-L102 gene therapy product has shown potential as a preventative measure if given early in the patient’s life
Finally, in the second half of this year, Rocket will be reporting results from its Phase 1 trial of RP-A501, a gene therapy for Danon disease. This condition causes dysfunction in heart, skeletal muscle, and brain cells and is caused by a mutation in the LAMP2B gene. The Phase 1 data is slated for release in 3Q22, and the company expects to follow up in 4Q22 with initiation of a Phase 2 pivotal study.
The company has plenty of ‘shots on goal’ in its research program, and plenty of catalysts ahead, with potential to positively impact the share price. Nevertheless, Rocket’s shares are down 69% in the past 12 months.
But it would seem that one insider is willing to buy the shares on the cheap. In recent days, Rocket’s CEO Gaurav Shah picked up 22,000 shares, spending $381,480.
Stifel analyst Dae Gon Ha isn’t worried by the low share price either. In fact, he sees it as an opportunity. In his view, the catalysts ahead are the key point, especially on the Danon disease track.
“As one of our Top Picks, we expected RP-A501 (Danon disease) update as the cornerstone of our thesis… Discussions with management provide additional reasons to like the setup in 2022 as LV programs mature and inch towards regulatory filing stage(s) backed by robust clinical data… As for Danon, pending regulatory discussions, we think an earlier commercialization cannot be ruled out (we estimate 2026E/2027E, US/EU) with 3Q22 update providing an important data point along the way. In all, we think there is a dislocation between RCKT’s inherent value (vs. market value today); continued progress across current pipeline could generate excitement,” Ha opined.
To this end, Ha rates RCKT stock a Buy, and his $63 price target suggests it has room for an impressive 231% upside in the coming year.
Overall, this stock has 6 analyst reviews on record – and they are all positive, making the analyst consensus a unanimous Strong Buy. The shares are priced at $19.03, and their average target of $66.67 implies an upside potential of 250%.
Source: Yahoo Finance
